Trevi Therapeutics (TRVI) Interest Coverage Ratio (2018 - 2026)
Trevi Therapeutics' (TRVI) quarterly Interest Coverage Ratio came in at 61.91 in Q1 2026, up 1.56% year-on-year from 60.96 in Q1 2025, and down 112.64% quarter-over-quarter from 29.12 in Q4 2025.
Trevi Therapeutics (TRVI) Interest Coverage Ratio (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Interest Coverage Ratio history runs 9 years deep, the most recent figure standing at 61.91 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 1.56% year-over-year to 61.91 in Q1 2026; TTM through Mar 2026 was 242.19, a 21.23% increase from a year earlier, with the FY2025 full-year figure at 0.6, up 86.5% from the prior year.
- Interest Coverage Ratio declined to 61.91 in Q1 2026 per TRVI's latest filing, from 29.12 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 8.37 in Q1 2024 and bottomed at 12243.0 in Q4 2024.
- The 5-year median for Interest Coverage Ratio is 29.12 (2025), against an average of 757.82.
- Across the five-year window, Interest Coverage Ratio plunged 23062.06% in 2024 and surged 99.76% in 2025, its largest moves.
- Year by year, Interest Coverage Ratio stood at 24.3 in 2022, then plunged by 117.56% to 52.86 in 2023, then plunged by 23062.06% to 12243.0 in 2024, then soared by 99.76% to 29.12 in 2025, then tumbled by 112.64% to 61.91 in 2026.
- Per Business Quant, the three latest TRVI Interest Coverage Ratio figures stand at 61.91 (Q1 2026), 29.12 (Q4 2025), and 14.85 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Trevi Therapeutics | 2.50 Bn | 2.50 Bn | - | -61.91 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -61.91 |
| Dec 31, 2025 | -29.12 |
| Sep 30, 2025 | -14.85 |
| Jun 30, 2025 | -13.35 |
| Mar 31, 2025 | -62.90 |
| Dec 31, 2024 | -12,243.00 |
| Sep 30, 2024 | -65.22 |
| Jun 30, 2024 | -9.88 |
| Mar 31, 2024 | -8.37 |
| Dec 31, 2023 | -52.86 |
| Sep 30, 2023 | -131.09 |
| Jun 30, 2023 | -54.78 |
| Mar 31, 2023 | -32.74 |
| Dec 31, 2022 | -24.30 |
| Sep 30, 2022 | -28.78 |
| Jun 30, 2022 | -26.51 |
| Mar 31, 2022 | -23.26 |
| Dec 31, 2021 | 28.53 |
| Sep 30, 2021 | -22.93 |
| Jun 30, 2021 | -24.45 |